Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04122976 · ClinicalTrials.gov registry record
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
A clinical trial of Prostate Cancer, sponsored by Bayer.
- Active
- Registry status
- 805
- Enrollment target
- 20
- Study locations
NCT04122976 is a study of Prostate Cancer that is active but no longer recruiting, run by Bayer. The registered enrollment target is 805 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (33% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04122976, a study of Prostate Cancer, is active but no longer recruiting, sponsored by Bayer.
- ACTIVE NOT RECRUITING
- Registry status
- 805 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.
Conditions Studied
Interventions
- DRUG Darolutamide(Nubeqa, BAY1841788)
Study Locations (20)
New York
- Beacon Cancer Care - Beacon
- Integrated Medical Professionals, PLLC - North New Hyde Park
- Premier Medical Group of the Hudson Valley, PC - Poughkeepsie
- Associated Medical Professional Urology - Syracuse
Florida
- Manatee Medical Research Institute - Bradenton
- Advanced Urology Institute - Daytona Beach
North Carolina
- Dukes Cancer Intitute Center for Prostate and Urologic Cancers - Durham
- Associated Urologists of NC - Raleigh
Alabama
- Urology Centers of Alabama - Homewood
Arizona
- Arizona Institute of Urology - Tucson
California
- Genesis Comprehensive Prostate Cancer Center - San Diego
Colorado
- The Urology Center of Colorado - Denver
Illinois
- Research by Design, LLC - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 805 participants |
| Start Date | 2020-01-30 |
| Est. Completion | 2026-10-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04122976
The ClinicalTrials.gov registry entry for NCT04122976 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 805 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (33% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Darolutamide(Nubeqa, BAY1841788) is the first listed.
NCT04122976 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04122976 about?
NCT04122976 is a clinical study titled "A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described". The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to tre...
What is the current status of trial NCT04122976?
This trial is currently active not recruiting. The enrollment target is 805 participants. The study started on 2020-01-30. Estimated completion is 2026-10-07.
What conditions does trial NCT04122976 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04122976?
The interventions under investigation include: Darolutamide(Nubeqa, BAY1841788) (DRUG).
Who is sponsoring clinical trial NCT04122976?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04122976 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.